Who Paid My Doc
A Phase 4, 52-Week (Primary Analysis at 24-Weeks), Randomized, Stratif
Research payments
$2,179,276
Through program year 2025, $2,179,276 in research payments was reported against A Phase 4, 52-Week (Primary Analysis at 24-Weeks), Randomized, Stratif, across 352 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,550,858 | 267 |
| 2024 | Research | $628,418 | 85 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Lorrie McGill Papillion, NE Named on 29 payments
- Anita Petteway North Miami Beach, FL Named on 21 payments
- Sashi Makam New Windsor, NY Named on 19 payments
- Ileana Rodicio Miami, FL Named on 19 payments
- Jaime Landman Fort Lauderdale, FL Named on 18 payments
- Barbara Baxter Dallas, TX Named on 16 payments
- Michael Palumbo Washington, PA Named on 15 payments
- Ronald Saff Tallahassee, FL Named on 14 payments
- Luis Castillo West Palm Beach, FL Named on 12 payments
- Guido Perez Miami, FL Named on 12 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.